Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis

We performed real world evidence (RWE) analysis of daratumumab, lenalidomide and dexamethasone (Dara-Rd) versus lenalidomide and dexamethasone (Rd) treatment in relapsed/refractory multiple myeloma patients (RRMM). In total, 240 RRMM patients were treated with Dara-Rd from 2016 to 2022 outside of cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Stork, Martin, Spicka, Ivan, Radocha, Jakub, Minarik, Jiri, Jelinek, Tomas, Jungova, Alexandra, Pavlicek, Petr, Pospisilova, Lenka, Sedlak, Frantisek, Straub, Jan, Pika, Tomas, Knechtova, Zdenka, Fidrichova, Anna, Boichuk, Ivanna, Sevcikova, Sabina, Maisnar, Vladimir, Hajek, Roman, Pour, Ludek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10182121/
https://www.ncbi.nlm.nih.gov/pubmed/37088816
http://dx.doi.org/10.1007/s00277-023-05188-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10182121/
https://www.ncbi.nlm.nih.gov/pubmed/37088816
http://dx.doi.org/10.1007/s00277-023-05188-4

Ejemplares similares